Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market
Figure 2: Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2020 and 2030
Figure 3: Global Microbiome Therapeutics Market (by Region), $Million, 2019-2030
Figure 2.1: Global Microbiome Therapeutics Market Segmentation
Figure 3.1: Global Microbiome Therapeutics Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Microbiome Therapeutics Market, $Million, 2019-2030
Figure 4.2: Historical Evolution of Microbiome
Figure 5.1: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 5.2: Patent Landscape of Microbiome Therapeutics Market (by Company and Region)
Figure 5.3: Key Players Financing Stratification
Figure 5.4: Financing Analysis, $Million, FY2017-3Q2020
Figure 5.5: Number of Pipeline Candidates (by Developmental Phase)
Figure 5.6: Number of Pipeline Candidates (by Route of Administration)
Figure 5.7: Number of Pipeline Candidates (by Type of Product)
Figure 5.8: Number of Pipeline Candidates (by Target Therapy Area)
Figure 6.1: Market Dynamics of Global Microbiome Therapeutics Market
Figure 6.2: Financing Activities Breakout, 2017-2019
Figure 6.3: Overall Financing Raised by Microbiome Companies, $Million, January 2017 – 3Q 2020
Figure 6.4: Synergistic Activities, 2017-2019
Figure 7.2: Synergistic Activities Share (by Company), January 2017-October 2020
Figure 7.3: Accreditations Share (by Company), January 2017- October 2020
Figure 7.4: Mergers and Acquisitions (by Company), January 2017- October 2020
Figure 7.5: Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019
Figure 7.6: Growth Share Analysis (by Geography)
Figure 7.7: Growth Share Analysis (by Company)
Figure 8.1: Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030
Figure 8.2: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications
Figure 8.3: Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030
Figure 8.4: Global Microbiome Therapeutics Market (Other Diseases), 2023-2030
Figure 9.1: Global Microbiome Therapeutics Market (by Region), 2020 and 2030
Figure 9.2: North America Microbiome Therapeutics Market, 2019-2030
Figure 9.3: North America: Market Dynamics
Figure 9.4: North America Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.5: U.S. Microbiome Therapeutics Market, 2019-2030
Figure 9.6: Canada Microbiome Therapeutics Market, 2019-2030
Figure 9.7: Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.8: Europe: Market Dynamics
Figure 9.9: Europe Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.10: France Microbiome Therapeutics Market, 2019-2030
Figure 9.11: Sweden Microbiome Therapeutics Market, 2019-2030
Figure 9.12: Germany Microbiome Therapeutics Market, 2019-2030
Figure 9.13: U.K. Microbiome Therapeutics Market, 2019-2030
Figure 9.14: Rest-of-Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.15: Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.16: Asia-Pacific: Market Dynamics
Figure 9.17: Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.18: Japan Microbiome Therapeutics Market, 2019-2030
Figure 9.19: Australia Microbiome Therapeutics Market, 2019-2030
Figure 9.20: China Microbiome Therapeutics Market, 2019-2030
Figure 9.21: India Microbiome Therapeutics Market, 2019-2030
Figure 9.22: Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.23: Rest-of-the-World Microbiome Therapeutics Market, 2019-2030
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: 4D Pharma plc: Overall Product Portfolio
Figure 10.3: 4D Pharma plc.: Overall Financials, 2018-2019
Figure 10.4: 4D Pharma plc: SWOT Analysis
Figure 10.5: AOBiome.: Overall Product Portfolio
Figure 10.6: AOBiome: SWOT Analysis
Figure 10.7: Finch Therapeutics: Overall Product Portfolio
Figure 10.8: Finch Therapeutics: SWOT Analysis
Figure 10.9: Rebiotix Inc.: Overall Product Portfolio
Figure 10.10: Rebiotix Inc.: SWOT Analysis
Figure 10.11: Immuron: Overall Product Portfolio
Figure 10.12: Immuron: Overall Financials, 2018-2020
Figure 10.13: Immuron: Research and Development Expenditure, 2018-2020
Figure 10.14: Immuron: SWOT Analysis
Figure 10.15: MaaT Pharma.: Overall Product Portfolio
Figure 10.16: MaaT Pharma: SWOT Analysis
Figure 10.17: Naked Biome: Overall Product Portfolio
Figure 10.18: Naked Biome: SWOT Analysis
Figure 10.19: OxThera AB: Overall Product Portfolio
Figure 10.20: OxThera AB: SWOT Analysis
Figure 10.21: Quorum Innovations, LLC: Overall Product Portfolio
Figure 10.22: Quorum Innovations, LLC: SWOT Analysis
Figure 10.23: Sanofi S.A.: Overall Product Portfolio
Figure 10.24: Sanofi S.A.: Overall Financials, 2017-2019
Figure 10.25: Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 10.26: Sanofi S.A.: Region Revenue, 2017-2019
Figure 10.27: Sanofi S.A.: Research and Development Expenditure, 2017-2019
Figure 10.28: Sanofi S.A.: SWOT Analysis
Figure 10.29: Seres Therapeutics, Inc.: Overall Product Portfolio
Figure 10.30: Seres Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 10.31: Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
Figure 10.32: Seres Therapeutics Inc.: SWOT Analysis
Figure 10.33: Synthetic Biologics, Inc.: Overall Product Portfolio
Figure 10.34: Synthetic Biologics, Inc.: Overall Financials, 2017-2019
Figure 10.35: Synthetic Biologics, Inc.: SWOT Analysis
Figure 10.36: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
Figure 10.37: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
Figure 10.38: Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
Figure 10.39: Taisho Pharmaceutical Co., Ltd. (by Region), 2019
Figure 10.40: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
Figure 10.41: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 10.42: Vedanta Biosciences, Inc.: Overall Product Portfolio
Figure 10.43: Vedanta Biosciences, Inc.: SWOT Analysis
Figure 10.44: Whole Genome Inc.: Overall Product Portfolio
Figure 10.45: Whole Biome Inc.: SWOT Analysis